Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05954546 · ClinicalTrials.gov registry record
A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 275
- Enrollment target
NCT05954546 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 275 participants.
The verdict
NCT05954546 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 275 participants
- Enrollment target
Study Summary
Brief summary The purpose of this study is to compare how effective, encorafenib plus binimetinib is in the real-world and clinical trial settings. And produce results to show that combining data on encorafenib plus binimetinib from both the real-world and clinical trial settings is possible for future research studies. This study group is identified from the database who: * Have taken at least 1 order or administration of encorafenib plus binimetinib treatment after the confirmation of having metastatic melanoma after 27 June 2018. * Are at least 18 years of age at the time of first encorafenib plus binimetinib initiation (index date). * Had never received encorafenib plus binimetinib or had received first-line immunotherapy at the start of the study. * Have ECOG status of 0 or 1 at the index date. * have available data on the number of deaths in an area or group of people. Patients will be followed from the date that the patient started the first encorafenib plus binimetinib treatment (treatment initiation) up to their last date of data availability. Last date of data availability could be the date of following events: patient lost to follow up at the clinic, death, or end of the database (January 2020). The database timeframe is June 2018 to January 2020.
Interventions
- DRUG Enco+bini
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2023-07-21 |
| Est. Completion | 2023-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05954546
The ClinicalTrials.gov registry entry for NCT05954546 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enco+bini is the first listed.
NCT05954546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05954546 about?
NCT05954546 is a clinical study titled "A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings". Brief summary The purpose of this study is to compare how effective, encorafenib plus binimetinib is in the real-world and clinical trial settings. And produce results to show that combining data on encorafenib plus binimetinib from both the real-world and clinical trial settings is possible for fut...
What is the current status of trial NCT05954546?
This trial is currently completed. The enrollment target is 275 participants. The study started on 2023-07-21. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT05954546?
The interventions under investigation include: Enco+bini (DRUG).
Who is sponsoring clinical trial NCT05954546?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.